Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Salvatore Alfieri

Fondazione IRCCS Istituto Nazionale dei Tumori

Italy

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacotherapy

50%

Oral And Maxillofacial Surgery

30%

Oral Cancer

40%

Cancer Therapy

40%

Radiation Therapy

30%

Oncology

30%

Melanoma

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles20

The Multifaceted Role of Growth Differentiation Factor 15 (GDF15): A Narrative Review from Cancer Cachexia to Target Therapy

Article Link

Year:

2025

Corrigendum to “Tumor molecular landscape of Epstein-Barr virus (EBV) related nasopharyngeal carcinoma in EBV-endemic and non-endemic areas: Implications for improving treatment modalities” [Transl. Res. 265 (2024) 1-16, (S1931524423001780), (10.1016/j.trsl.2023.10.004)]

Article Link

Year:

2025

Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial

Article Link

Year:

2025

Improving the multidisciplinary therapeutic management of head and neck squamous cell carcinoma: Consensus statements from an Italian expert panel

Article Link

Year:

2025

Lenvatinib in Relapsed/Metastatic Adenoid Cystic Carcinoma: Real-World Data From 17 Italian Centers

Article Link

Year:

2025

Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide in head and neck cancer: the CONFRONT phase I-II trial

Article Link

Year:

2025

Adenoid Cystic carcinoma of minor salivary glands (AdCCmSG): a multidisciplinary update

Article Link

Year:

2024

Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study

Article Link

Year:

2024

HER2-targeted therapies for salivary gland cancers

Article Link

Year:

2024

Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go?

Article Link

Year:

2023

Prognostic factors in salvage surgery for recurrent head and neck cancer: A systematic review and meta-analysis.

Article Link

Year:

2021

Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial.

Article Link

Year:

2021

Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.

Article Link

Year:

2021

Modelling Radiation-Induced Salivary Dysfunction during IMRT and Chemotherapy for Nasopharyngeal Cancer Patients.

Article Link

Year:

2021

A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Efficacy of Aqualief<sup>TM</sup> Mucoadhesive Tablets in Head and Neck Cancer Patients Who Developed Radiation-Induced Xerostomia.

Article Link

Year:

2021

Prognostic role of pre-treatment magnetic resonance imaging (MRI)-based radiomic analysis in effectively cured head and neck squamous cell carcinoma (HNSCC) patients.

Article Link

Year:

2021

Late toxicities burden in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib.

Article Link

Year:

2021

Monitoring patients with head and neck cancer for flu-like symptoms during the COVID-19 pandemic.

Article Link

Year:

2021

Prognostic Nutritional Index Predicts Toxicity in Head and Neck Cancer Patients Treated with Definitive Radiotherapy in Association with Chemotherapy

Article Link

Year:

2021

The appropriate use of circulating EBV-DNA in nasopharyngeal carcinoma: Comprehensive clinical practice guidelines evaluation.

Article Link

Year:

2021

Collaborators10

Lisa Licitra

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

Nicola Alessandro Iacovelli

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

LUCA TONDULLI

Head of Medical Oncology

Provincia autonoma di Bolzano - Alto Adige

ITALY

Stefano Bondi

Candiolo Cancer Institute

ITALY

Laura Deborah Locati

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

Paolo Bossi

University of Brescia

ITALY

mattia lauriola

Associate Professor

University of Bologna

ITALY

Stefano Cavalieri

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

Carlo Resteghini

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

Cristiana Bergamini

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

How do I reach out?

Meet Kite AI